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To the editor: In May 2018, an unscheduled analysis from the Botswana-Harvard AIDS 
Institute Partnership Tsepamo birth-outcomes surveillance study showed a higher prevalence 
of neural-tube defects among infants born to women who were using dolutegravir-based 
antiretroviral treatment (ART) regimens at the time of conception relative to infants born to 
women taking other types of ART.1 In response to this safety signal, the Botswana Ministry 
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of Health and Wellness expanded surveillance for neural-tube defects in selected non-
Tsepamo health facilities.
The Ministry of Health and Wellness surveillance system followed a protocol that had been 
approved by the institutional review boards of the Botswana Health Research Development 
Committee, the Centers for Disease Control and Prevention, and the University of Maryland, 
Baltimore, and included all pregnancies in which live-born or stillborn infants were 
delivered at more than 24 weeks of gestation at 22 non-Tsepamo facilities from October 
2018 through March 2019. The end date of March 31, 2019, was chosen in light of the 
anticipated change in practice associated with the 2018 data release from the Tsepamo study, 
which was expected to result in a decrease in the number of pregnancies with 
periconceptional exposure to dolutegravir.
Midwives conducted systematic surface examinations of all live-born and stillborn infants. 
Information regarding maternal human immunodeficiency virus (HIV) infection status, ART 
exposure at conception, and infant examination findings was collected. Data on the use of 
folate supplements and other medications, including antiepileptic medications, were 
abstracted only in cases in which a neural-tube defect was found. Data on folate use before 
pregnancy were not available. A clinical geneticist who was unaware of maternal HIV 
infection and ART exposure status reviewed and classified suspected neural-tube defects. 
We estimated the prevalence of neural-tube defects according to maternal HIV infection and 
ART status and differences in prevalence relative to pregnancies in which mothers had been 
taking dolutegravir at conception, with 95% confidence intervals calculated by the exact 
binomial2 and the Newcombe–Wilson hybrid score3 methods, respectively.
During the study period, the surveillance system captured 3076 deliveries (3064 singleton 
and 12 twin); 2328 (76%) were among HIV-negative women, 742 (24%) were among HIV-
positive women, and 6 (<1%) were among women with an unknown HIV status. At the time 
of conception, the majority (544 [73%]) of HIV-positive mothers were taking ART; of these, 
152 (28%) were taking dolutegravir. Six suspected neural-tube defects were initially 
identified among all the infants; one was confirmed as a neural-tube defect by surgical 
records (a case of spina bifida), two were classified as probable neural-tube defects on the 
basis of clinical description and surgical referral (one case of spina bifida and one case of 
spina bifida plus frontal encephalocele), and two were excluded on the basis of records 
consistent with a sacral dimple. The final suspected neural-tube defect (a lesion on the side 
of the head) was classified as “possible” because the available information was insufficient 
to either confirm it or rule it out. Single-gene causes of isolated neural-tube defects are 
unlikely, and genetic testing was not performed for the three confirmed or probable cases in 
this analysis.
The final analyses included only the three confirmed or probable neural-tube defects (Table 
1). One neural-tube defect was found among the 152 deliveries in which the mother had 
been taking dolutegravir at conception (prevalence, 0.66%; 95% confidence interval [CI], 
0.02 to 3.69), and two neural-tube defects were found among the 2326 deliveries in which 
the mother was HIV-negative (prevalence, 0.09%; 95% CI, 0.01 to 0.31). The difference in 
the prevalence of neural-tube defects between deliveries in which the mothers had been 
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taking non–dolutegravir-based ART at conception and those among mothers who had been 
taking dolutegravir-based ART at conception was 0.66 percentage points (95% CI, −0.48 to 
3.63). We conducted a sensitivity analysis to assess how inclusion of the possible neural-
tube defect, which occurred in an infant born to an HIV-negative woman, would affect the 
estimate of the difference in prevalence and found no meaningful change.
Our findings suggest a slightly higher prevalence of neural-tube defects among deliveries in 
which the mothers were HIV-positive and had been taking dolutegravir at the time of 
conception than among deliveries in which the mothers were HIV-negative. However, 
because of the short duration of our study and the infrequent occurrence of neural-tube 
defects in the general population, the number of cases identified was small, the prevalence 
estimates were unstable, and the resultant differences in prevalence had confidence intervals 
that included the null value. These data suggest that the magnitude of the risk of neural-tube 
defects associated with dolutegravir exposure at the time of conception remains less than 
1%, which is consistent with findings from the Tsepamo study (now published in the 
Journal)4 and important in individual decision making regarding ART options. Although our 
findings are independent from those of the Tsepamo study, together they represent coverage 
of more than 90% of all births in Botswana. These findings should be considered in an 
assessment of global data to further examine ART exposure and adverse birth outcomes.
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